HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin : an association with glucose-lowering effects

Files in This Item:
64_EJ16-0295.pdf657.05 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/68415

Title: Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin : an association with glucose-lowering effects
Authors: Takase, Takahiro Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Yamamoto, Chiho Browse this author
Atsumi, Tatsuya Browse this author →KAKEN DB
Keywords: Fatty liver
Ipragliflozin
Issue Date: Mar-2017
Publisher: The Japan Endocrine Society
Journal Title: Endocrine Journal
Volume: 64
Issue: 3
Start Page: 363
End Page: 367
Publisher DOI: 10.1507/endocrj.EJ16-0295
PMID: 27980239
Abstract: In this study, we investigated the ameliorating effects of ipragliflozin on fatty liver in patients with type 2 diabetes. The factors that influenced the amelioration of fatty liver were also examined. Analysis included data of 21 Japanese patients with type 2 diabetes obtained from our prospective observational study. After obtaining patients' informed consent, once-daily ipragliflozin (50 mg/day) was given for 16 weeks. In addition to several clinical parameters, body composition was also compared before and after 16 weeks of treatment. The extent of fatty liver was estimated using a fatty liver index (FLI). After 16 weeks, FLI significantly decreased, from 70.1 ± 19.4 to 60.3 ± 25.5 (p = 0.0009) as well as levels of fasting plasma glucose (FPG), HbA1c, body weight, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT) and fat mass. To reveal the factors influencing the FLI changes observed on ipragliflozin treatment, correlations between changes in FLI and several other measured parameters were examined. Changes in FPG (correlation coefficient = 0.4683, p = 0.0323) and HbA1c (correlation coefficient = 0.4383, p = 0.0469) showed significant positive correlations with changes in FLI. On the other hand, no correlations of changes in FLI were observed with body weight, VAT, SAT nor fat mass. In conclusion, ipragliflozin ameliorated FLI in Japanese patients with type 2 diabetes. Improvement in FLI was associated with that of glucose intolerance.
Type: article
URI: http://hdl.handle.net/2115/68415
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University